Abstract
Nanobodies (Nbs) are great molecular tools that can circumvent the limitations of traditional antibodies such as large size, low stability, slow clearance, and high immunogenicity. Recent studies identified several clinical applications of Nbs targeting various cancers. Cancer stem cells (CSCs) comprise a limited subpopulation of cancer cells that can reproduce autonomously and differentiate into diverse cancer lineages. CSCs are responsible for providing resistance against chemotherapy and radiotherapy. Various studies focused on targeting these CSCs via Nbs to selectively reduce the cancer burden. Nbs have the potential to reduce the CSCs and thereby could halt the progression of specific cancers.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ahmadvand D, Rasaee MJ, Rahbarizadeh F, Kontermann RE, Sheikholislami F (2009) Cell selection and characterization of a novel human endothelial cell specific nanobody. Mol Immunol 46:1814–1823. https://doi.org/10.1016/j.molimm.2009.01.021
Albert S et al (2017) A novel nanobody-based target module for retargeting of T lymphocytes to EGFR-expressing cancer cells via the modular UniCAR platform. OncoImmunology 6:e1287246. https://doi.org/10.1080/2162402X.2017.1287246
Allegra A et al (2018) Nanobodies and cancer: current status and new perspectives. Cancer Investig 36:221–237. https://doi.org/10.1080/07357907.2018.1458858
Altintas I et al (2013) Nanobody-albumin nanoparticles (NANAPs) for the delivery of a multikinase inhibitor 17864 to EGFR overexpressing tumor cells. J Control Release 165:110–118
An N et al (2018) Anti-multiple myeloma activity of nanobody-based anti-CD38 chimeric antigen receptor T cells. Mol Pharm 15:4577–4588. https://doi.org/10.1021/acs.molpharmaceut.8b00584
Araste F, Ebrahimizadeh W, Rasooli I, Rajabibazl M, Mousavi Gargari SL (2014) A novel VHH nanobody against the active site (the CA domain) of tumor-associated, carbonic anhydrase isoform IX and its usefulness for cancer diagnosis. Biotechnol Lett 36:21–28. https://doi.org/10.1007/s10529-013-1340-1
Bachran C et al (2017) The activity of myeloid cell-specific VHH immunotoxins is target-, epitope-, subset- and organ dependent. Sci Rep 7:17916. https://doi.org/10.1038/s41598-017-17948-0
Baharlou R et al (2018) An antibody fragment against human delta-like ligand-4 for inhibition of cell proliferation and neovascularization. Immunopharmacol Immunotoxicol 40:368–374. https://doi.org/10.1080/08923973.2018.1505907
Bandhavkar S (2016) Cancer stem cells: a metastasizing menace! Cancer Med 5:649–655. https://doi.org/10.1002/cam4.629
Bathula NV, Bommadevara H, Hayes JM (2021) Nanobodies: the future of antibody-based immune therapeutics. Cancer Biother Radiopharm 36(2):109–122
Behdani M et al (2013) Development of VEGFR2-specific nanobody pseudomonas exotoxin A conjugated to provide efficient inhibition of tumor cell growth. New Biotechnol 30:205–209. https://doi.org/10.1016/j.nbt.2012.09.002
Bobkov V et al (2018) Nanobody-Fc constructs targeting chemokine receptor CXCR4 potently inhibit signaling and CXCR4-mediated HIV-entry and induce antibody effector functions. Biochem Pharmacol 158:413–424. https://doi.org/10.1016/j.bcp.2018.10.014
Bouchkouj N et al (2019) FDA approval summary: Axicabtagene Ciloleucel for relapsed or refractory large B-cell lymphoma. Clin Cancer Res 25:1702–1708. https://doi.org/10.1158/1078-0432.Ccr-18-2743
Colak S, Medema JP (2014) Cancer stem cells—important players in tumor therapy resistance. FEBS J 281:4779–4791. https://doi.org/10.1111/febs.13023
Cortez-Retamozo V et al (2004) Efficient cancer therapy with a nanobody-based conjugate. Cancer Res 64:2853–2857. https://doi.org/10.1158/0008-5472.Can-03-3935
D’Huyvetter M et al (2021) Phase I trial of 131I-GMIB-Anti-HER2-VHH1, a new promising candidate for HER2-targeted radionuclide therapy in breast cancer patients. J Nucl Med 62:1097–1105. https://doi.org/10.2967/jnumed.120.255679
De Munter S et al (2020) Rapid and effective generation of nanobody based CARs using PCR and Gibson Assembly. Int J Mol Sci 21. https://doi.org/10.3390/ijms21030883
Deng C et al (2017) Novel recombinant immunotoxin of EGFR specific nanobody fused with cucurmosin, construction and antitumor efficiency in vitro. Oncotarget 8:38568–38580. https://doi.org/10.18632/oncotarget.16930
Farajpour Z, Rahbarizadeh F, Kazemi B, Ahmadvand D (2014) A nanobody directed to a functional epitope on VEGF, as a novel strategy for cancer treatment. Biochem Biophys Res Commun 446:132–136. https://doi.org/10.1016/j.bbrc.2014.02.069
Fay F, Scott CJ (2011) Antibody-targeted nanoparticles for cancer therapy. Immunotherapy 3:381–394. https://doi.org/10.2217/imt.11.5
Fenderico N et al (2019) Anti-LRP5/6 VHHs promote differentiation of Wnt-hypersensitive intestinal stem cells. Nat Commun 10:365. https://doi.org/10.1038/s41467-018-08172-z
Fumey W et al (2017) Nanobodies effectively modulate the enzymatic activity of CD38 and allow specific imaging of CD38(+) tumors in mouse models in vivo. Sci Rep 7:14289. https://doi.org/10.1038/s41598-017-14112-6
Glaser T, Han I, Wu L, Zeng X (2017) Targeted nanotechnology in glioblastoma multiforme. Front Pharmacol 8:166. https://doi.org/10.3389/fphar.2017.00166
Gorovits B, Koren E (2019) Immunogenicity of chimeric antigen receptor T-cell therapeutics. BioDrugs 33:275–284. https://doi.org/10.1007/s40259-019-00354-5
Groot AJ et al (2006) Identification by phage display of single-domain antibody fragments specific for the ODD domain in hypoxia-inducible factor 1alpha. Lab Investig 86:345–356. https://doi.org/10.1038/labinvest.3700395
Guardiola S et al (2018) Blocking EGFR activation with anti-EGF nanobodies via two distinct molecular recognition mechanisms. Angew Chem Int Ed 57:13843–13847. https://doi.org/10.1002/anie.201807736
Hajari Taheri F et al (2019) T cell engineered with a novel nanobody-based chimeric antigen receptor against VEGFR2 as a candidate for tumor immunotherapy. IUBMB Life 71:1259–1267. https://doi.org/10.1002/iub.2019
Hamers-Casterman C et al (1993) Naturally occurring antibodies devoid of light chains. Nature 363:446–448. https://doi.org/10.1038/363446a0
Hassani M et al (2019) Construction of a chimeric antigen receptor bearing a nanobody against prostate a specific membrane antigen in prostate cancer. J Cell Biochem 120:10787–10795. https://doi.org/10.1002/jcb.28370
He L, Gu J, Lim LY, Yuan ZX, Mo J (2016) Nanomedicine-mediated therapies to target breast cancer stem cells. Front Pharmacol 7:313. https://doi.org/10.3389/fphar.2016.00313
Helma J, Cardoso MC, Muyldermans S, Leonhardt H (2015) Nanobodies and recombinant binders in cell biology. J Cell Biol 209:633–644. https://doi.org/10.1083/jcb.201409074
Huang R, Rofstad EK (2016) Cancer stem cells (CSCs), cervical CSCs and targeted therapies. Oncotarget 8
Huet HA et al (2014) Multivalent nanobodies targeting death receptor 5 elicit superior tumor cell killing through efficient caspase induction. MAbs 6:1560–1570. https://doi.org/10.4161/19420862.2014.975099
Inoue A, Sawata SY, Taira K, Wadhwa R (2007) Loss-of-function screening by randomized intracellular antibodies: identification of hnRNP-K as a potential target for metastasis. Proc Natl Acad Sci U S A 104:8983–8988. https://doi.org/10.1073/pnas.0607595104
Jamnani FR et al (2014) T cells expressing VHH-directed oligoclonal chimeric HER2 antigen receptors: towards tumor-directed oligoclonal T cell therapy. Biochim Biophys Acta 1840:378–386. https://doi.org/10.1016/j.bbagen.2013.09.029
June CH, O'Connor RS, Kawalekar OU, Ghassemi S, Milone MC (2018) CAR T cell immunotherapy for human cancer. Science 359:1361–1365. https://doi.org/10.1126/science.aar6711
Kavousipour S et al (2018) A comparison between cell, protein and peptide-based approaches for selection of nanobodies against CD44 from a synthetic library. Protein Pept Lett 25:580–588. https://doi.org/10.2174/0929866525666180530122159
Keyaerts M et al (2016) Phase I study of 68Ga-HER2-nanobody for PET/CT assessment of HER2 expression in breast carcinoma. J Nucl Med 57:27–33. https://doi.org/10.2967/jnumed.115.162024
Khatibi AS, Roodbari NH, Majidzade-A K, Yaghmaei P, Farahmand L (2019) In vivo tumor-suppressing and anti-angiogenic activities of a recombinant anti-CD3ε nanobody in breast cancer mice model. Immunotherapy 11:1555–1567. https://doi.org/10.2217/imt-2019-0068
Li B, Li Q, Mo J, Dai H (2017) Drug-loaded polymeric nanoparticles for cancer stem cell targeting. Front Pharmacol 8:51. https://doi.org/10.3389/fphar.2017.00051
Li T et al (2016) Immuno-targeting the multifunctional CD38 using nanobody. Sci Rep 6:27055. https://doi.org/10.1038/srep27055
Liu F et al (2016) Drug discovery via human-derived stem cell organoids. Front Pharmacol 7:334. https://doi.org/10.3389/fphar.2016.00334
Long AH et al (2015) 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med 21:581–590. https://doi.org/10.1038/nm.3838
Lu B, Huang X, Mo J, Zhao W (2016) Drug delivery using nanoparticles for cancer stem-like cell targeting. Front Pharmacol 7:84
Marhaba R et al (2008) CD44 and EpCAM: cancer-initiating cell markers. Curr Mol Med 8:784–804. https://doi.org/10.2174/156652408786733667
Mimori K et al (2003) Costimulatory signals distinctively affect CD20- and B-cell-antigen-receptor-mediated apoptosis in Burkitt's lymphoma/leukemia cells. Leukemia 17:1164–1174. https://doi.org/10.1038/sj.leu.2402936
Minchinton AI, Tannock IF (2006) Drug penetration in solid tumours. Nat Rev Cancer 6:583–592. https://doi.org/10.1038/nrc1893
Ming Y et al (2017) Circulating tumor cells: from theory to nanotechnology-based detection. Front Pharmacol 8:35. https://doi.org/10.3389/fphar.2017.00035
Mullard A (2017) Parkinson disease repurposing promise. Nat Rev Drug Discov 16:669. https://doi.org/10.1038/nrd.2017.198
Mullard A (2021a) Blood-brain barrier-traversing biologic secures regulatory approval, in Japan. Nat Rev Drug Discov 20:332. https://doi.org/10.1038/d41573-021-00066-y
Mullard A (2021b) Parkinson pipeline pare back. Nat Rev Drug Discov 20:166. https://doi.org/10.1038/d41573-021-00030-w
Nadler LM et al (1980) Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Res 40:3147–3154
Oliveira S, Heukers R, Sornkom J, Kok RJ, van Bergen en Henegouwen PMP (2013) Targeting tumors with nanobodies for cancer imaging and therapy. J Control Release 172:607–617. https://doi.org/10.1016/j.jconrel.2013.08.298
Oliveira S et al (2010) Downregulation of EGFR by a novel multivalent nanobody-liposome platform. J Control Release 145:165–175
Papadopoulos KP et al (2015) Unexpected hepatotoxicity in a phase I study of TAS266, a novel tetravalent agonistic nanobody® targeting the DR5 receptor. Cancer Chemother Pharmacol 75:887–895. https://doi.org/10.1007/s00280-015-2712-0
Peled A, Wald O, Burger J (2012) Development of novel CXCR4-based therapeutics. Expert Opin Investig Drugs 21:341–353. https://doi.org/10.1517/13543784.2012.656197
Pirzer T et al (2018) Generation of potent anti-HER1/2 immunotoxins by protein ligation using split Inteins. ACS Chem Biol 13:2058–2066. https://doi.org/10.1021/acschembio.8b00222
Porčnik A et al (2021) TRIM28 selective nanobody reduces glioblastoma stem cell invasion. Molecules 26:5141
Prasad V (2018) Immunotherapy: Tisagenlecleucel—the first approved CAR-T-cell therapy: implications for payers and policy makers. Nat Rev Clin Oncol 15:11–12. https://doi.org/10.1038/nrclinonc.2017.156
Qin W, Huang G, Chen Z, Zhang Y (2017a) Nanomaterials in targeting cancer stem cells for cancer therapy. Front Pharmacol 8:1. https://doi.org/10.3389/fphar.2017.00001
Qin W, Zheng Y, Qian BZ, Zhao M (2017b) Prostate cancer stem cells and nanotechnology: a focus on Wnt signaling. Front Pharmacol 8:153. https://doi.org/10.3389/fphar.2017.00153
Raje N et al (2019) Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med 380:1726–1737. https://doi.org/10.1056/NEJMoa1817226
Ramsey DM, McAlpine SR (2013) Halting metastasis through CXCR4 inhibition. Bioorg Med Chem Lett 23:20–25. https://doi.org/10.1016/j.bmcl.2012.10.138
Reshadmanesh A, Rahbarizadeh F, Ahmadvand D, Jafari Iri Sofla F (2018) Evaluation of cellular and transcriptional targeting of breast cancer stem cells via anti-HER2 nanobody conjugated PAMAM dendrimers. Artif Cells Nanomed Biotechnol 46:S105–S115. https://doi.org/10.1080/21691401.2018.1489269
Romão E et al (2020) Identification of nanobodies against the acute myeloid Leukemia marker CD33. Int J Mol Sci 21:310
Roovers RC et al (2007) Efficient inhibition of EGFR signalling and of tumour growth by antagonistic anti-EGFR nanobodies. Cancer Immunol Immunother 56:303–317. https://doi.org/10.1007/s00262-006-0180-4
Roovers RC et al (2011) A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth. Int J Cancer 129:2013–2024. https://doi.org/10.1002/ijc.26145
Safarzadeh Kozani P et al (2022) Nanobody-based CAR-T cells for cancer immunotherapy. Biomark Res 10:24. https://doi.org/10.1186/s40364-022-00371-7
Saha S, Adhikary A, Bhattacharyya P, Das T, Sa G (2012) Death by design: where curcumin sensitizes drug-resistant tumours. Anticancer Res 32:2567–2584
Samec N et al (2018) Glioblastoma-specific anti-TUFM nanobody for in-vitro immunoimaging and cancer stem cell targeting. Oncotarget 9
Schoonaert L et al (2017) Identification and characterization of nanobodies targeting the EphA4 receptor. J Biol Chem 292:11452–11465. https://doi.org/10.1074/jbc.M116.774141
Sharifzadeh Z et al (2013) Genetically engineered T cells bearing chimeric nanoconstructed receptors harboring TAG-72-specific camelid single domain antibodies as targeting agents. Cancer Lett 334:237–244. https://doi.org/10.1016/j.canlet.2012.08.010
Shen Z, Sang Z, Shi Y (2022) Nanobodies as a powerful platform for biomedicine. Trends Mol Med 28:1006–1007. https://doi.org/10.1016/j.molmed.2022.08.007
Sotiropoulou PA, Christodoulou MS, Silvani A, Herold-Mende C, Passarella D (2014) Chemical approaches to targeting drug resistance in cancer stem cells. Drug Discov Today 19:1547–1562. https://doi.org/10.1016/j.drudis.2014.05.002
Sun W et al (2012) A combined strategy improves the solubility of aggregation-prone single-chain variable fragment antibodies. Protein Expr Purif 83:21–29. https://doi.org/10.1016/j.pep.2012.02.006
Talelli M et al (2011) Reprint of "nanobody—Shell functionalized thermosensitive core-crosslinked polymeric micelles for active drug targeting". J Control Release 153:93–102
Talelli M et al (2013) Intrinsically active nanobody-modified polymeric micelles for tumor-targeted combination therapy. Biomaterials 34:1255–1260
Tang J et al (2016) Novel CD7-specific nanobody-based immunotoxins potently enhanced apoptosis of CD7-positive malignant cells. Oncotarget 7:34070–34083. https://doi.org/10.18632/oncotarget.8710
Tijink BM et al (2008) Improved tumor targeting of anti-epidermal growth factor receptor nanobodies through albumin binding: taking advantage of modular nanobody technology. Mol Cancer Ther 7:2288–2297. https://doi.org/10.1158/1535-7163.Mct-07-2384
Van Der Meel R et al (2012) Tumor-targeted nanobullets: anti-EGFR nanobody-liposomes loaded with anti-IGF-1R kinase inhibitor for cancer treatment. J Control Release 159:281–289
Voelker R (2020) FDA targets illegal hangover relief. Jama 324:832. https://doi.org/10.1001/jama.2020.15849
Vosjan MJWD et al (2012) Nanobodies targeting the hepatocyte growth factor: potential new drugs for molecular cancer therapy. Mol Cancer Ther 11:1017–1025. https://doi.org/10.1158/1535-7163.Mct-11-0891
Wang H, Meng AM, Li SH, Zhou XL (2017) A nanobody targeting carcinoembryonic antigen as a promising molecular probe for non-small cell lung cancer. Mol Med Rep 16:625–630. https://doi.org/10.3892/mmr.2017.6677
Wang H et al (2019) Human domain antibodies to conserved epitopes on HER2 potently inhibit growth of HER2-overexpressing human breast cancer cells in vitro. Antibodies 8:25
Wang J, Zheng Y, Zhao M (2016) Exosome-based cancer therapy: implication for targeting cancer stem cells. Front Pharmacol 7:533. https://doi.org/10.3389/fphar.2016.00533
Wingler LM, McMahon C, Staus DP, Lefkowitz RJ, Kruse AC (2019) Distinctive activation mechanism for angiotensin receptor revealed by a synthetic nanobody. Cell 176:479–490.e412. https://doi.org/10.1016/j.cell.2018.12.006
Yi Y, Hsieh IY, Huang X, Li J, Zhao W (2016) Glioblastoma stem-like cells: characteristics, microenvironment, and therapy. Front Pharmacol 7:477. https://doi.org/10.3389/fphar.2016.00477
Yu Y et al (2017) Humanized CD7 nanobody-based immunotoxins exhibit promising anti-T-cell acute lymphoblastic leukemia potential. Int J Nanomedicine 12:1969–1983. https://doi.org/10.2147/ijn.S127575
Yuan ZX et al (2016) Targeting strategies for renal cell carcinoma: from renal cancer cells to renal cancer stem cells. Front Pharmacol 7:423. https://doi.org/10.3389/fphar.2016.00423
Zah E, Lin M-Y, Silva-Benedict A, Jensen MC, Chen YY (2016) T cells expressing CD19/CD20 bispecific chimeric antigen receptors prevent antigen escape by malignant B cells. Cancer Immunol Res 4:498–508. https://doi.org/10.1158/2326-6066.Cir-15-0231
Zhang F et al (2017) Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade. Cell Discov 3:17004. https://doi.org/10.1038/celldisc.2017.4
Zhang M et al (2021) A single-arm, open-label, pilot trial of autologous CD7-CAR-T cells for CD7 positive relapsed and refractory T-lymphoblastic leukemia/lymphoma. Blood 138:3829–3829. https://doi.org/10.1182/blood-2021-149999
Conflict of Interest
None.
Author information
Authors and Affiliations
Corresponding authors
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Islam, M.S., Gopalan, V., Islam, F. (2023). Engineering Nanobody Targeting Cancer Stem Cells. In: Islam, F., Lam, A.K. (eds) Cancer Stem Cells: Basic Concept and Therapeutic Implications. Springer, Singapore. https://doi.org/10.1007/978-981-99-3185-9_14
Download citation
DOI: https://doi.org/10.1007/978-981-99-3185-9_14
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-99-3184-2
Online ISBN: 978-981-99-3185-9
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)